Seres Therapeutics (MCRB) Invested Capital (2014 - 2024)

Seres Therapeutics has disclosed Invested Capital across 11 years of filings, most recently posting $13.8 million for Q4 2024.

• In Q4 2024, Invested Capital fell 75.68% year-over-year to $13.8 million; the TTM figure through Dec 2024 stood at $13.8 million (down 75.68% YoY), while the FY2024 annual figure was $13.8 million, down 75.68% from the prior year.
• Invested Capital came in at $13.8 million for Q4 2024 at Seres Therapeutics, down from $23.9 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $213.0 million in Q3 2020 to a low of -$40.7 million in Q2 2020.
• Average Invested Capital over 5 years is $86.9 million, with a median of $79.9 million recorded in 2022.
• Year-over-year, Invested Capital tumbled 97.44% in 2023 and surged 1156.94% in 2024.
• Over 5 years, Invested Capital stood at $199.8 million in 2020, then dropped by 21.86% to $156.2 million in 2021, then sank by 60.4% to $61.8 million in 2022, then dropped by 8.32% to $56.7 million in 2023, then plunged by 75.68% to $13.8 million in 2024.
• Per Business Quant data, the three most recent Invested Capital figures were $13.8 million in Q4 2024, $23.9 million in Q3 2024, and $15.4 million in Q2 2024.